Gafrik Research

Flash Note

November 9, 2026

H1 2026

GEVORKYAN ® a. s.

Powder Metallurgy Plant

Gafrik Research

November 9, 2026

Flash Note

This report supplements the Flash Note dated July 9, 2026 (Q1 2026). Full coverage at www.gafrikresearch.com

GEVORKYAN, a.s. (GEV.PR) | Central Europe

H1 2026

COMPANY INFORMATION	
Name	GEVORKYAN, a.s.
Industry	Industrial Machinery & Equipment
Sector	Industrials
Sub-sector	Powder Metallurgy Components
Headquarters	Vlkanová, Slovakia
Employees	170 (175 period-end)
Exchanges	Prague (Primary) / Bratislava
Tickers	GEV.PR / 1GVR001E
ISIN	SK1000025322

RATING & TARGET PRICE	
Rating	BUY (Affirmed)
Target Price	CZK 280 / EUR 11.49
Upside	*+61.8 %*
Prior Rating (July 9, 2026)	BUY
Prior Target (July 9, 2026)	CZK 292 / EUR 12.02

SHARE DATA	
Current Price (November 6, 2026)	EUR 7.11
	CZK 173
Price (July 9, 2026)	EUR 7.99
	CZK 194
IPO Price (June 2022)	EUR 10.10
	CZK 248
52-Week High	EUR 10.12
	CZK 246
52-Week Low	EUR 7.11
	CZK 173
Market Cap	EUR 127.0M
	CZK 3 089M
Shares Outstanding (post-ABB)	17 857 272
Free Float	*28.04 %*

VALUATION SUMMARY	
Method	EV/EBITDA
Trailing EBITDA (FY2025 norm.)	EUR 29M
Forward EBITDA (2026E guidance low)	EUR 33M
Target Multiple	9.7x
Net Debt (30.06.2026)	EUR 95.5M
Net Debt / LTM EBITDA	3.2x
EV/EBITDA current (trailing)	7.7x

FX: EUR/CZK 24.345, ČNB reference fixing, November 6, 2026. Market prices: Prague Stock Exchange, last close before publication. Free float: GEVORKYAN 7,39/31 bond prospectus dated October 23, 2026 (previously 30%).



Source: Prague Stock Exchange | Edit: Gafrik Research

EVENT SUMMARY

Gafrik Research publishes this Flash Note as a material-event response combining the H1 2026 interim results of GEVORKYAN, a.s. (IFRS, unaudited, internal management reporting, released September 15, 2026), the H1 2026 investor call, and the completion of the EUR 30M bond refinancing, announced on November 4, 2026. Publication was timed to the refinancing so that the dominant near-term uncertainty, the November 2026 bond maturity, could be resolved in the rating rather than left open. The prior (July 9) rating validity lapsed at the H1 results; coverage is re-anchored here.

H1 2026 results. Revenue reached EUR 49.811M (+18.18% YoY) and EBITDA EUR 15.039M (+9.19% YoY) at a margin of 30.19%. The sequential optics versus the reported Q1 2026 margin of 39.6% overstate any compression: the Q1 figure was inflated by an Other Operating Result timing item (EUR +2.282M) and, stripped of it, the underlying Q1 margin was approximately 30%. The H1 margin of 30.19% is in line with the approximately 30% FY2026 margin indicated in the October 23, 2026 bond prospectus, a normalisation rather than a deterioration below trend. Management attributes the residual softness to Italian production volumes moved to Slovakia at a lower margin, described as possibly one-off.

The read. The operating story holds; the weight of the case has moved to the balance sheet and to execution. H1 free cash flow was approximately EUR -9.8M (operating cash flow EUR 4.3M against capex EUR 14.1M) and was funded by the March equity raise, not by operations; the 2027 cash-flow inflection is not yet visible on reported data. The refinancing is resolved (debt-for-debt, no SPO), but at a higher 7.39% coupon, and covenant headroom is thin. The equity story now rests on margin recovery after the Italian consolidation and on the FCF turn, neither of which H1 evidences.

Valuation. Gafrik Research reaffirms **BUY** with a revised target of **EUR 11.49 / CZK 280** (from EUR 12.02 / CZK 292), reflecting updated net debt of EUR 95.5M from the H1 balance sheet. The multiple (9.7x) and the trailing/forward EBITDA bases are unchanged; the target reduction is mechanical and not a deterioration; gross financial debt is broadly flat across the year (EUR 95.3M at year-end 2025, EUR 95.9M at H1 2026). The prior note anchored on the Q1 net debt of EUR 86.0M, a temporary trough created by the March equity-raise proceeds, which were deployed to capex over H1. Scenario probabilities are held at Bear 20% / Base 60% / Bull 20% (unchanged from July 9): the completed refinancing removes the prior refinancing-failure tail, but the bear case is redefined as an operational and leverage down-case, and newly disclosed negatives (H1 FCF of EUR -9.8M, the related-party receivable, thin covenant headroom and the higher coupon) justify holding rather than reducing the bear weight.

IMPORTANT DISCLOSURES

This report has been commissioned by GEVORKYAN, a.s. (issuer-sponsored research). The analytical view and all conclusions are based solely on Gafrik Research s.r.o.'s independent analysis. GEVORKYAN, a.s. did not influence the analytical view or content.

This analytical view is NOT a personal investment recommendation. Investors should assess suitability for their individual circumstances and consult a qualified financial advisor before making any investment decision.

Report Type: Flash Note
Methodology: www.gafrikresearch.com/methodology
Rating Validity: Until 9M 2026 (November 24, 2026) or material event

Gafrik Research s.r.o.
Dipl. Ing. Miroslav Gáfrik
EQUITY ANALYST
mirogafrik@gafrikresearch.com

This report is for information purposes only and should not be considered a solicitation to buy or sell any security. Neither Gafrik Research s.r.o. nor any other party guarantees its accuracy or makes warranties regarding results from its usage. Redistribution is prohibited without the express written consent of Gafrik Research s.r.o. Copyright (c) 2025–2026. All rights reserved.

GEVORKYAN, a.s. (GEV.PR) | Central Europe

H1 2026

INCOME STATEMENT (thousands EUR)

	H1 '26	H1 '25	YoY
Revenue	**49 811**	**42 150**	*+18%*
of which: Products	**45 250**	**37 311**	*+21%*
of which: Services	**4 561**	**4 839**	*-6%*
Change in Inventories of Own Production	**889**	**1 931**	*n.m.*
Material & Energy	**-21 475**	**-18 715**	*+15%*
Services (external)	**-10 734**	**-9 099**	*+18%*
Personnel Costs	**-3 341**	**-2 938**	*+14%*
Other Operating Result	**-111**	**444**	*n.m.*
EBITDA	**15 039**	**13 773**	*+9%*
EBITDA Margin	*30.19%*	*32.68%*	*-2.49pp*
D&A	**-8 364**	**-8 601**	*–3%*
EBIT	**6 675**	**5 172**	*+29%*
Financial Result (net)	**-1 453**	**-1 289**	*+13%*
EBT	**5 222**	**3 883**	*+34%*
Net Profit (EAT)	**3 969**	**2 951**	*+35%*

BALANCE SHEET (thousands EUR)

	H1 '26	YE '25	vs YE
PP&E	**135 183**	**130 816**	*+3%*
Intangibles	**10 800**	**10 952**	*-1%*
Inventories	**35 360**	**33 898**	*+4%*
Trade receivables	**34 881**	**35 512**	*-2%*
Cash & Equivalents	**410**	**378**	*+8%*
Total Assets	**218 752**	**212 225**	*+3%*
Total Equity	**90 924**	**78 160**	*+16%*
Bonds issued	**38 363**	**38 903**	*-1%*
Loans & borrowings	**57 344**	**56 135**	*+2%*
Lease liabilities	**237**	**326**	*-27%*
Gross financial debt	**95 944**	**95 264**	*+1%*
Net Debt	**95 534**	**94 886**	*+1%*
Net Debt / LTM EBITDA	**3.2x**		-

CASH FLOW (thousands EUR)

	H1 '26
Operating cash flow	**4 319**
Capex (PP&E + intangibles)	**-14 077**
Implied free cash flow	**-9 758**
Equity raise (share subscription)	**+9 405**
Net borrowings and other financing	**+385**
Net change in cash	**+32**
Cash, end of period	**410**

All financial data complies with IFRS standards

Total equity rose EUR 12.8M versus year-end (from EUR 78.2M to EUR 90.9M): the March share subscription (EUR 9.4M) plus H1 net profit (EUR 4.0M), less minor items. The increase is largely the equity raise, not retained earnings.

IMPORTANT DISCLOSURES

This report has been commissioned by GEVORKYAN, a.s. (issuer-sponsored research). The analytical view and all conclusions are based solely on Gafrik Research s.r.o.'s independent analysis. GEVORKYAN, a.s. did not influence the analytical view or content.

This analytical view is NOT a personal investment recommendation. Investors should assess suitability for their individual circumstances and consult a qualified financial advisor before making any investment decision.

Report Type: Flash Note
Methodology: www.gafrikresearch.com/methodology
Rating Validity: Until 9M 2026 (November 24, 2026) or material event

Gafrik Research s.r.o.
Dipl. Ing. Miroslav Gáfrik
EQUITY ANALYST
mirogafrik@gafrikresearch.com

H1 2026 RESULTS: ANALYTICAL COMMENTARY (CONTINUED)

Revenue. GEVORKYAN reported H1 2026 revenue of EUR 49.811M (+18.18% YoY), comprising product revenue of EUR 45.250M (from EUR 37.311M) and service revenue of EUR 4.561M (from EUR 4.839M). On an annualised basis, H1 revenue implies a run-rate of approximately EUR 99.6M, which sits below the midpoint of the FY2026 revenue range of EUR 96-110M in the company's updated financial plan (midpoint EUR 103M). On a straight run-rate the full year lands in the lower half of the range; management expects a stronger H2.

EBITDA and margin. Reported EBITDA reached EUR 15.039M (+9.19% YoY) at a margin of 30.19% (versus 32.68% in H1 2025). Consumption of materials and energy rose to EUR 21.475M (+14.7% YoY), consistent with a continued mix-shift toward higher-specification materials. The 30.19% half-year margin is in line with the underlying Q1 rate once the Other Operating Result item is excluded, and in line with the approximately 30% FY2026 margin indicated in the bond prospectus. The genuine margin test lies ahead: Gevorkyan Sinteris Italia, a lower-margin operation, enters the group numbers only from the December 31, 2026 consolidation.

Below the line. EBIT reached EUR 6.675M (+29.06% YoY), supported by a modest reduction in D&A to EUR 8.364M (from EUR 8.601M). EBT grew +34.48% to EUR 5.222M and net profit (EAT) +34.50% to EUR 3.969M, with profit growth materially outpacing revenue, consistent with operating leverage below the EBITDA line and a lower D&A base. Note that the headline +34.5% is the most leveraged figure in the set; the operating rate is EBITDA +9.2% on a falling margin.

Cash flow (now disclosed in the interim statements). H1 operating cash flow was EUR 4.319M. Purchases of property, plant, equipment and intangibles (capex) were EUR 14.077M. Implied free cash flow for H1 was therefore approximately **EUR -9.8M**, covered by the March equity raise (EUR 9.405M in share subscription proceeds). Operating cash conversion was weak at 29% (OCF 4.3M on EBITDA 15.0M). On reported data the 2027 free-cash-flow inflection is not yet visible: H1 free cash flow is materially negative and was funded by equity, not operations.

Balance sheet and liquidity. Cash fell to EUR 0.410M (from EUR 2.192M at H1 2025; EUR 0.378M at year-end 2025). Current assets of EUR 72.763M broadly match current liabilities of EUR 72.840M, but the current-asset side is inventories and receivables, not cash. Liquidity is managed through receivables conversion and overdraft facilities: a UniCredit facility of up to EUR 13.0M (drawn EUR 11.157M) and a Komerční banka facility of up to EUR 5.5M (drawn EUR 3.083M). Undrawn headroom on these lines is therefore limited.

Related-party transactions. GEVORKYAN CZ, s.r.o. is a sister company that issued the EUR 30M bond maturing on November 16, 2026 and lent the proceeds to GEVORKYAN, a.s. under a loan maturing on the same date (EUR 30.040M at June 30, 2026); interest on this loan was EUR 0.688M in H1 2026 (FY2025: EUR 1.377M). The refinancing is discussed under Capital Structure.

Debt and leverage. Gross financial debt at June 30, 2026 was EUR 95.944M (bonds EUR 38.363M, loans and borrowings EUR 57.344M, lease liabilities EUR 0.237M); net debt was EUR 95.534M. Net debt is broadly flat versus year-end (gross financial debt EUR 95.264M at December 31, 2025) but up approximately EUR 9.6M versus Q1 (net debt EUR 85.959M at March 31, 2026), as the March ABB-related reduction in short-term debt reversed by mid-year. Trailing Net Debt/LTM EBITDA (LTM EUR 30.3M) is approximately 3.2x, in line with management's 3.2 - 3.3x. The binding covenant is the Komerční banka Net Debt/EBITDA threshold of 3.5x. At that threshold on LTM EBITDA the net-debt ceiling is approximately EUR 106M, leaving headroom of roughly EUR 10.5M; H1 alone consumed EUR 9.8M of free cash flow. The new GEVORKYAN 7,39/31 bonds add a separate Net Debt/EBITDA covenant, tested semi-annually on a trailing 12-month basis from December 31, 2026: 3.75x for 2026, 3.50x for 2027 and 3.25x from 2028 onwards, alongside a minimum interest cover of 4.0x. The bond limit is looser than the bank threshold this year but becomes the binding constraint from 2028, at a level close to the current 3.2x; any breach must be publicly disclosed. The Komerční banka debt-service-coverage covenant was not met at December 31, 2025 and a waiver was obtained; at June 30, 2026 all covenants, including the debt-service-coverage ratio, were met. Covenants are tested quarterly and management states it has no indication of a breach over the next 12 months. See Risks for the year-end consolidation effect on this ratio.

Investment cycle. Management confirmed the 2023-2026 capex cycle is nearing completion, with capex expected to decline to maintenance levels of EUR 18-22M from 2027. On our estimates this turns free cash flow modestly positive from 2027 (order of EUR 5-10M), materially below the pace of EBITDA, given cash interest (now higher after the 7.39% refinancing) and working-capital needs; we do not carry the EUR 15-20M positive-FCF figure implied by prior framing, as that would require operating cash flow of EUR 33-42M, at or above the FY2026 EBITDA plan of EUR 33 - 37M. The H1 call also described continued expansion (a further hall, eight CNC/robotised lines, a move to four shifts), which, if sustained, would defer the inflection. We therefore treat the 2027 inflection as management-guided rather than evidenced.

Gevorkyan Sinteris Italia. The acquisition (Bologna, powder metallurgy) completed on April 22, 2026 and added a number of new customers. Deliveries to Rheinmetall and other defence-industry customers are confirmed (per the H1 call); current revenue run-rate is of the order of several million EUR annually (management: "in the order of millions"; the EUR 10-15M figure is a Gafrik Research estimate). Consolidation into group statements occurs as of December 31, 2026, with quarterly consolidated reporting from 2027. Until then the Italian contribution is unverifiable on a standalone basis, is treated as option value, and is excluded from the base valuation.

CAPITAL STRUCTURE UPDATE

Debt structure (June 30, 2026). Total financial debt of EUR 95.944M comprises bonds of EUR 38.363M (GEVORKYAN 8.50/2028, ISIN CZ0000001813, EUR 8.363M; GEVORKYAN 7.11/2029, ISIN CZ0000002159, EUR 30.000M), loans and borrowings of EUR 57.344M (long-term EUR 8.599M, short-term EUR 48.745M, including sale-and-leaseback), and lease liabilities of EUR 0.237M. Net debt of EUR 95.534M.

Refinancing: material event (post balance-sheet date). As of the H1 balance-sheet date, the EUR 30M bonds issued by sister entity GEVORKYAN CZ, s.r.o. (ISIN CZ0003535809, coupon 4.5%, maturity November 16, 2026) represented an active, unresolved refinancing risk. On November 4, 2026, GEVORKYAN, a.s. announced the completion of a new EUR 30M bond issue (issue date October 30, 2026; fixed coupon 7.39% p.a., maturity October 30, 2031, issuer: GEVORKYAN, a.s.; ISIN CZ0003588287, "GEVORKYAN 7,39/31") to refinance the maturing GEVORKYAN CZ bonds. The transaction was debt-for-debt (no SPO); the issue size was held at EUR 30M despite oversubscription, consistent with the stated objective of gradual deleveraging. This resolves the primary near-term risk identified in prior coverage. The new bond is a direct obligation of GEVORKYAN, a.s. (the EUR 100M guarantee previously extended to the GEVORKYAN CZ bonds does not apply to the issuer's own obligation). The proceeds are used, via a loan to GEVORKYAN CZ, solely to repay the maturing issue, replacing the EUR 30.040M intercompany loan currently within loans and borrowings. Total debt is therefore unchanged, but EUR 30M moves from loans and borrowings to bonds. The higher coupon (7.39% versus 4.5%) raises forward annual interest cost on this tranche by approximately EUR 0.9M, a modest headwind to future free cash flow.

This report is for information purposes only and should not be considered a solicitation to buy or sell any security. Neither Gafrik Research s.r.o. nor any other party guarantees its accuracy or makes warranties regarding results from its usage. Redistribution is prohibited without the express written consent of Gafrik Research s.r.o. Copyright (c) 2025–2026. All rights reserved.

GEVORKYAN, a.s. (GEV.PR) | Central Europe

H1 2026

VALUATION UPDATE

Gafrik Research applies the EV/EBITDA peer-multiples approach as the primary method, consistent with prior reports and with the company's capital-intensive, investment-phase profile under the published methodology. The target multiple of 9.7x and the blended framework (equal weighting to trailing FY2025 normalised EBITDA of EUR 29.0M and forward FY2026 EBITDA of EUR 33.0M, the low end of the EUR 33-37M range in the updated financial plan published with the H1 2026 interim report) are unchanged from prior coverage. The bond prospectus of October 23, 2026 states a wider EUR 30-40M range with the same EUR 35M midpoint; at a forward EBITDA of EUR 30M, the target would be EUR 10.67 / CZK 260, with the rating unchanged. The peer group (Sandvik, AMETEK, Carpenter Technology, ATI, Kennametal) is as defined in the Initiating Quarter Report of February 5, 2026; it is a broad diversified-industrial set rather than a pure-play powder-metallurgy comparison, so the headline discount to that peer median is not a reliable standalone value signal. The forthcoming deep dive will address this with a tighter pure-play peer set and will also test the 9.7x multiple against cash generation (EV/(EBITDA – capex) and FCF yield), given the revised 2027 free-cash-flow outlook. The only input revised versus the July 9 Flash Note is net debt, updated to EUR 95.534M from the H1 2026 balance sheet; the resulting target reduction (CZK 292 to CZK 280) corrects the anchor to a normalised net debt rather than the transient Q1 cash position and is not driven by incremental leverage.

Component	EBITDA	Multiple	Target EV	Net Debt	Equity Value	TP/share
Trailing FY2025 (norm.)	**EUR 29M**	9.7x	**EUR 281.3M**	**EUR 95.534M**	**EUR 185.8M**	**EUR 10.40**
Forward 2026E (guidance low)	**EUR 33M**	9.7x	**EUR 320.1M**	**EUR 95.534M**	**EUR 224.6M**	**EUR 12.58**
Blended (50% / 50%)	-	-	-	-	-	**EUR 11.49**

CZK derived at EUR/CZK 24.345 (06.11.2026). Upside stated on the CZK base. Target Price: EUR 11.49 / CZK 280. Upside +61.8% versus CZK 173 (06.11.2026). Rating: BUY.

SCENARIO ANALYSIS

Upside is computed on the CZK base against CZK 173. The weighted target (CZK 279) sits marginally below the base case (CZK 280) because the bear case lies further below the base than the bull case lies above it.

Bear case (20%). Margin fails to recover off the 30% low, the Italian integration adds one-off costs, the de-rating persists, and a further half-year of negative free cash flow (no equity support) lifts net debt toward EUR 105M. On LTM EBITDA of EUR 30M at 7.5x (close to the current market multiple) this yields CZK 164, a 5.2% downside.

Base case (60%). Blended valuation at 9.7x. Assumes the FY2026 trajectory holds, margin recovers toward plan following the Italian consolidation, and free cash flow improves progressively from 2027. This is the published target: CZK 280 / EUR 11.49.

Bull case (20%). 2026E EBITDA of EUR 36.5M, near the top of the EUR 33-37M plan range, valued on forward EBITDA alone with a partial re-rating to 10.5x. Conditional on disclosure of a specific defence contract (customer and value), a Sinteris revenue trajectory toward EUR 30M, and an earlier FCF inflection.

Going-concern basis. The refinancing-failure tail modelled as a scope exclusion in prior notes no longer applies, as the refinancing was completed (announced November 4, 2026); the bear case is accordingly redefined as an operational and leverage down-case. Scenario probabilities are the analyst's judgment, held at 20/60/20 (unchanged from July 9): the removal of the refinancing tail is offset by newly disclosed negatives, so the bear weight is held rather than reduced.

Scenario	Prob.	EBITDA	Multiple	Net Debt	TP EUR	TP CZK	Upside
Bear	20 %	EUR 30.0M (LTM, no growth)	7.5x	EUR 105M	6.72	164	-5.2 %
Base	60 %	Blended 29M / 33M	9.7x	EUR 95.5M	11.49	280	+61.8 %
Bull	20 %	EUR 36.5M	10.5x	EUR 95.5M	16.11	392	+126.6 %
Weighted	**100 %**	-	-		**11.46**	**279**	**+61.3 %**

CATALYSTS AND RISKS

CATALYSTS

- 9M 2026 results (November 2026): first test of the H2 acceleration needed for the EUR 33 - 37M EBITDA plan.
- FCF inflection from 2027 (capex EUR 18-22M), free cash flow modestly positive on our estimates.
- Sinteris Italia integration; first consolidated figures in FY2026 statements.
- Disclosure of a named defence contract (customer and value), supporting partial re-rating.
- Polish defence JV with prospect of a Warsaw listing; further M&A optionality. Neither is in the base case.

RISKS

- **Covenants and year-end consolidation (primary near-term).** Net Debt/LTM EBITDA of approximately 3.2x against the Komerční banka 3.5x threshold leaves roughly EUR 10.5M of headroom, while H1 burned EUR 9.8M of free cash flow; the bond covenant tightens to 3.25x from 2028. The December 31, 2026 consolidation adds Sinteris debt before a full year of its EBITDA, which can lift the ratio mechanically at year-end.
- **Margin / Italy integration.** H1 margin of 30.2% at the low end of the plan; the Italian margin profile enters only from Q4 2026, so the test is ahead.
- **FCF timing.** H1 free cash flow of approximately EUR -9.8M was funded by equity; the 2027 inflection is a forward assumption, and the 7.39% coupon raises the hurdle.
- **Refinancing (resolved).** EUR 30M refinanced debt-for-debt (issue date October 30, 2026); residual risk is the higher coupon (+EUR 0.9M p.a.).
- **Reporting transition.** Subsidiary contributions unverifiable until the first consolidation at December 31, 2026.

IMPORTANT DISCLOSURES

This report has been commissioned by GEVORKYAN, a.s. (issuer-sponsored research). The analytical view and all conclusions are based solely on Gafrik Research s.r.o.'s independent analysis. GEVORKYAN, a.s. did not influence the analytical view or content.

This analytical view is NOT a personal investment recommendation. Investors should assess suitability for their individual circumstances and consult a qualified financial advisor before making any investment decision.

Report Type: Flash Note
Methodology: www.gafrikresearch.com/methodology
Rating Validity: Until 9M 2026 (November 24, 2026) or material event

Gafrik Research s.r.o.
Dipl. Ing. Miroslav Gáfrik
EQUITY ANALYST
mirogafrik@gafrikresearch.com

This report is for information purposes only and should not be considered a solicitation to buy or sell any security. Neither Gafrik Research s.r.o. nor any other party guarantees its accuracy or makes warranties regarding results from its usage. Redistribution is prohibited without the express written consent of Gafrik Research s.r.o. Copyright (c) 2025–2026. All rights reserved.

GEVORKYAN, a.s. (GEV.PR) | Central Europe

H1 2026

CONTACT

Gafrik Research s.r.o.

Independent Equity Research

T. G. Masaryka 349/13

984 01 Lučenec, Slovakia

European Union

GAFRIK RESEARCH ANALYTICAL METHODOLOGY

Our analytical framework estimates the total expected shareholder return over a 12-month horizon. The model combines quantitative factors (peer multiples, financial strength, cash flow generation) with qualitative factors (industry outlook, management execution, catalyst timing). Qualitative analysis is used primarily to challenge and stress-test valuation assumptions. Scenario probabilities represent analytical judgment and are updated as new information becomes available. Target prices are derived from quantitative valuation methods. Qualitative factors influence scenario probabilities and valuation assumptions but do not directly determine target prices.

Rating Framework

Gafrik Research uses a 12-month investment horizon for its ratings. Our recommendations are based on the Expected Total Shareholder Return (TSR), which includes share price appreciation and dividend yield.

Rating	Expected Return	Criteria & Characteristics
BUY	> +15 %	Significant upside potential with a valid identifiable catalyst within the horizon.
HOLD	-10 % to +15 %	Fairly valued, or upside > 15 % but lacking near-term catalysts or facing elevated execution uncertainty.
SELL	< -10 %	Significant overvaluation or material impairment of the fundamental investment thesis.

Note: Rating band definitions have been aligned with the published methodology (HOLD -10% to +15%, SELL below -10%). Reports dated February 5 through May 18, 2026 stated the HOLD band as -15% to +15%. This change has no impact on any current or historical rating.

RECOMMENDATION HISTORY (12 MONTHS)

Date	Report Type	Rating	Target Price	Price at Date
February 5, 2026	**Initiating Quarter**	BUY (Initiation)	EUR 12.34 / CZK 303	EUR 9.78 / CZK 240
March 30, 2026	Flash Note	**BUY (Affirmed)**	**EUR 11.01 / CZK 270**	**EUR 7.84 / CZK 192**
May 18, 2026	**Ad Hoc Rating Update**	**BUY (Affirmed)**	**EUR 12.07 / CZK 296**	**EUR 7.58 / CZK 186**
July 9, 2026	**Flash Note**	**BUY (Affirmed)**	**EUR 12.02 / CZK 292**	**EUR 7.99 / CZK 194**
November 9, 2026	**Flash Note**	**BUY (Affirmed)**	**EUR 11.49 / CZK 280**	**EUR 7.11 / CZK 173**

Prices are the last close before publication (source: Prague Stock Exchange). Rating distribution: BUY 100% (1/1 covered issuers). Issuer-sponsored research: 100% (1/1 covered issuers).

Valuation Approach

The valuation methodology is tailored to the specific characteristics of the company:

·DCF is the primary method for mature, cash-generative businesses with predictable free cash flows.

·Peer multiples are primarily applied to capital-intensive companies, businesses in an investment phase, or cyclical industries.

·In selected cases, a weighted blended approach is applied, reflecting the relative confidence in each valuation method.

All valuations incorporate scenario analysis (Bear/Base/Bull cases with probability weighting) to assess sensitivity to key assumptions and execution risks.

Quality Control Process

Each report undergoes a structured quality control process, including:

· Financial statement analysis and IFRS data verification,

· Management interviews, where applicable,

· Peer benchmarking (minimum of five comparable companies),

· Valuation modeling with sensitivity analysis,

· Risk assessment, covering capital structure, liquidity, execution risk, and market risks.

Publication Cycle & Rating Validity

Reports are published on a quarterly basis for covered companies (Initialising Report, Quarterly Reports, Annual Report and special Deep Dive analysis), with ad-hoc updates in the event of material developments.

Ratings remain valid until the next quarterly results or the occurrence of a material event requiring revalidation. Any rating changes are fully disclosed and justified in subsequent reports.

Independence & Conflicts of Interest

Issuer-sponsored research, where applicable, is explicitly disclosed.

All analytical views are based solely on independent analysis.

The analyst holds no financial interests in the covered companies.

Compensation is structured as a fixed fee, independent of rating outcomes.

Method selection and weighting reflect the company's business model, capital intensity, and position within the investment cycle, rather than a fixed methodological hierarchy.

Full methodology: www.gafrikresearch.com/methodology

IMPORTANT DISCLOSURES

This report has been commissioned by GEVORKYAN, a.s. (issuer-sponsored research). The analytical view and all conclusions are based solely on Gafrik Research s.r.o.'s independent analysis. GEVORKYAN, a.s. did not influence the analytical view or content.

This analytical view is NOT a personal investment recommendation. Investors should assess suitability for their individual circumstances and consult a qualified financial advisor before making any investment decision.

Report Type: Flash Note
Methodology: www.gafrikresearch.com/methodology
Rating Validity: Until 9M 2026 (November 24, 2026) or material event

Gafrik Research s.r.o.
Dipl. Ing. Miroslav Gáfrik
EQUITY ANALYST
mirogafrik@gafrikresearch.com

This report is for information purposes only and should not be considered a solicitation to buy or sell any security. Neither Gafrik Research s.r.o. nor any other party guarantees its accuracy or makes warranties regarding results from its usage. Redistribution is prohibited without the express written consent of Gafrik Research s.r.o. Copyright (c) 2025–2026. All rights reserved.

GEVORKYAN, a.s. (GEV.PR) | Central Europe

H1 2026

ANALYST

Dipl. Ing. Miroslav Gáfrik

Equity Analyst

mirogafrik@gafrikresearch.com

www.gafrikresearch.com

DISCLAIMERS & LEGAL INFORMATION

General Notice

This research report (the "Report") has been prepared by Gafrik Research s.r.o. ("Gafrik Research") for informational and educational purposes only. This Report does not constitute an offer to buy or sell, or a solicitation of an offer to buy or sell, any financial instruments or to participate in any particular trading strategy.

No Investment Advice

The information and opinions contained herein do not constitute personal investment advice. This Report has been prepared without regard to the individual financial circumstances, investment objectives, or risk tolerance of any specific recipient. Investors should independently evaluate each issuer and security and consult with a qualified financial advisor before making any investment decisions.

Issuer-Sponsored Research

This Report is "Issuer-Sponsored Research," meaning Gafrik Research has been compensated by the subject company (the "Issuer") for the preparation and distribution of this analysis. However, Gafrik Research maintains full editorial independence. The Issuer had no influence over the valuation models, target price determination, or the final rating (BUY/HOLD/SELL) assigned in this Report.

Accuracy of Information

While Gafrik Research has obtained information from sources believed to be reliable, we do not guarantee its accuracy, completeness, or timeliness. All estimates, projections, and opinions constitute the judgment of the analyst as of the date of this Report and are subject to change without notice. Past performance is not indicative of future results.

Conflicts of Interest & Trading

Gafrik Research and its analysts are subject to internal policies regarding the management of conflicts of interest. Analysts are prohibited from trading in the securities of the Issuer during "Blackout Periods" (48 hours before and after the publication of a report). The analyst who prepared this Report holds no financial interests (shares, options, or derivatives) in the subject company.

Distribution and Copyright

This Report is intended for distribution only in jurisdictions where such distribution is permitted by law. Any unauthorized use, duplication, or redistribution of this Report is strictly prohibited. This report is available on the LSEG/Refinitiv platform under issuer coverage for GEVORKYAN, a.s. (GEV.PR).


© 2025-2026 Gafrik Research s.r.o. All rights reserved.

Analyst Certification

The analyst(s) responsible for the preparation of this research report hereby certify that:

- Independence of Views: All of the views expressed in this report accurately reflect the analyst's personal views about the subject company and its securities.
- No Compensation Link: No part of the analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations, target prices, or views expressed in this report.
- Objective Basis: This report is based on professional analysis of publicly available information. The analyst has not received any non-public, price-sensitive information from the issuer that could influence the conclusions of this report.
- Conflict Disclosure: Neither the analyst nor any person closely associated with the analyst holds a financial interest in the securities of the subject company.

Analyst Name: Dipl. Ing. Miroslav Gáfrik
Date: November 9, 2026
Firm: Gafrik Research s.r.o.



This report is for information purposes only and should not be considered a solicitation to buy or sell any security. Neither Gafrik Research s.r.o. nor any other party guarantees its accuracy or makes warranties regarding results from its usage. Redistribution is prohibited without the express written consent of Gafrik Research s.r.o. Copyright (c) 2025–2026. All rights reserved.